IGC Pharma, Inc. carried $134K in long-term debt against $405K in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 2.2% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters IGC Pharma, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IGC Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-KT | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $134K-2.2% | $137K-2.8% | $141K-2.1% | $144K-47.8% | $276Kn/m | $0 | N/A | N/A | $452K-43.6% | $801K+147.4% | $324Kn/m | $0-100.0% | $1.8M | N/A | N/A |
| Cash & Equivalents | $405K-66.2% | $1.2M-62.5% | $3.2M-69.4% | $10.5M-28.1% | $14.5M+100.4% | $7.3M-71.7% | $25.6M+1444.6% | $1.7M+208.2% | $538K-63.9% | $1.5M+80.8% | $824K-19.7% | $1.0M-3.6% | $1.1M+89.1% | $563K-64.4% | $1.6M |
IGC Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $128K-4.5% | $149K+10.4% | $191K+40.4% | $131K-4.4% | $132K-2.2% | $133K-2.2% | $134K-2.2% | $134K-2.9% | $135K-2.9% | $136K-2.9% | $137K-2.8% | $138K-2.1% |
| Cash & Equivalents | $377K-19.8% | $331K-78.6% | $207K-88.7% | $900K-24.9% | $1.1M-28.5% | $454K-75.1% | $405K-66.2% | $470K-65.9% | $1.5M-48.9% | $1.8M+5.9% | $1.2M-62.5% | $1.4M-72.1% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More IGC Pharma, Inc. financials
Frequently Asked Questions
IGC Pharma, Inc. carried $134K in long-term debt against $405K in cash and equivalents at the end of fiscal year 2025.
IGC Pharma, Inc. (IGC) long-term debt fell by 2.2% year over year, from $137K to $134K in fiscal year 2025.
IGC Pharma, Inc. (IGC) reported $128K in long-term debt in Q3 2026. This represents a decrease of 4.5% from the same quarter a year earlier.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what IGC Pharma, Inc. (IGC) reported on that line in every period on record.